Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

Janus Kinase inhibitors (JAKis) are approved for the management of several chronic inflammatory diseases, from rheumatic conditions, to dermatological and ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...

Spinal deformities such as scoliosis and kyphosis are among the most serious complications of neurofibromatosis type 1 (NF1), a genetic disorder that affects about one in 3,000 people.

Poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors have been described in a Protheragen Inc. patent as potentially useful for the treatment of cancer, neurodegeneration, cardiovascular disorders ...

A few years ago, I had a patient who affectionately went by the name “Pops.” At 85 years young, he was full of life and juggling multiple health issues alongside prostate cancer, yet determined not to ...